Sanofi drops two clinical assets; reports rebounding Dupixent sales

Sanofi (Euronext:SAN; NYSE:SNY) disclosed in its 2Q18 earnings that it ended development of antibody-drug conjugate (ADC) SAR566658 to treat triple-negative breast cancer (TNBC), as well as a recombinant subunit vaccine to treat tuberculosis.

A Sanofi spokesperson told BioCentury that based on Phase II data, it determined SAR566658's efficacy and safety profile was not "sufficient to make a meaningful difference for patients." SAR566658 was in a registrational Phase II trial to treat TNBC. Sanofi did not respond in time for publication to inquiries regarding whether it has plans to develop the ADC for other tumor types...